Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.16058
Abstract: This cross-sectional study evaluates the cost per event averted in adjuvant cancer trials between January 2018 and March 2022. read more here.
Keywords: cost per; per event; cancer trials; event averted ... See more keywords
Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2018.6205
Abstract: Recent legislative efforts such as the 21st Century Cures Act have emphasized capturing and communicating the patient experience. Patient-reported outcome (PRO) assessments are one method to measure symptoms, function, and health-related quality of life. In… read more here.
Keywords: open label; cancer trials; cancer; patient reported ... See more keywords
Participant Protection in Phase 1 Pediatric Cancer Trials
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Pediatrics"
DOI: 10.1001/jamapediatrics.2018.3629
Abstract: Advances in pediatric cancer treatment represent one of modern medicine’s greatest achievements. This progress would not be possible without testing new therapies in children. However, pediatric research must satisfy stricter ethical and regulatory standards than… read more here.
Keywords: phase pediatric; cancer trials; participant protection; cancer ... See more keywords
Statistical justification of expansion cohorts in phase 1 cancer trials
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31577
Abstract: Phase I cancer trials increasingly incorporate dose‐expansion cohorts (DECs), reflecting a growing demand to acquire more information about investigational drugs. Protocols commonly fail to provide a sample‐size justification or analysis plan for the DEC. In… read more here.
Keywords: cancer; phase cancer; expansion cohorts; cancer trials ... See more keywords
Evaluation of toxicities for intravesical drugs in phase 1 bladder cancer trials
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34508
Abstract: Improving clinical trial design is important for optimizing approval of safe and effective drugs. Phase 1 clinical trials seek to determine phase 2 doses by investigating predefined dose‐limiting toxicities. Traditional definitions of dose‐limiting toxicity may… read more here.
Keywords: cancer trials; bladder cancer; cancer; drugs phase ... See more keywords
Unfinished business: Terminated cancer trials and the relevance of treatment intent, sponsors and intervention types
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33342
Abstract: The aim of the study was to report on the association of trial sponsors with intervention type, treatment intent, recruitment success and reasons to terminate cancer trials. The ClinicalTrials database was searched for interventional Phase… read more here.
Keywords: intent; industry; cancer trials; sponsored trials ... See more keywords
A nonparametric Bayesian method for dose finding in drug combinations cancer trials
Sign Up to like & getrecommendations! Published in 2022 at "Statistics in Medicine"
DOI: 10.1002/sim.9316
Abstract: We propose an adaptive design for early‐phase drug‐combination cancer trials with the goal of estimating the maximum tolerated dose (MTD). A nonparametric Bayesian model, using beta priors truncated to the set of partially ordered dose… read more here.
Keywords: drug; cancer trials; nonparametric bayesian; bayesian method ... See more keywords
Gender and sex disparity in cancer trials
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000773
Abstract: The study population within phase III clinical trials leading to approval of new cancer agents should ideally more closely mirror the population who will ultimately receive these agents. Although the number of females participating in… read more here.
Keywords: cancer trials; clinical trials; cancer; gender sex ... See more keywords
Surrogate Endpoint ID'd for Prostate Cancer Trials.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-121
Abstract: Metastasis-free survival is a strong surrogate for overall survival for men with localized prostate cancer, a meta-analysis shows. The intermediate outcome measure could help accelerate the evaluation of novel adjuvant therapies in this patient population. read more here.
Keywords: prostate cancer; cancer trials; cancer; surrogate endpoint ... See more keywords
Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework
Sign Up to like & getrecommendations! Published in 2020 at "Trials"
DOI: 10.1186/s13063-020-04425-9
Abstract: Introduction An impactful clinical trial will have real-life benefits for patients and society beyond the academic environment. This study analyses case studies of cancer trials to understand how impact is evidenced for cancer trials and… read more here.
Keywords: research; trial; impact; case studies ... See more keywords
The Impact of a National Cyberattack Affecting Clinical Trials: The Cancer Trials Ireland Experience.
Sign Up to like & getrecommendations! Published in 2023 at "JCO clinical cancer informatics"
DOI: 10.1200/cci.22.00149
Abstract: PURPOSE Cyberattacks are increasing in health care and cause immediate disruption to patient care, have a lasting impact, and compromise scientific integrity of affected clinical trials. On the May 14, 2021, the Irish health service… read more here.
Keywords: cyberattack; clinical trials; cancer trials; cancer ... See more keywords